Connection Between Epigenome, Selective Mutability, Evolution, and Human Disease
Li, Harris et al., PLoS Genetics
Researchers at the Baylor College of Medicine and elsewhere propose a "connection between the epigenome, selective mutability, evolution, and human disease" based on the findings of their study on associations of structural mutability with germline DNA methylation and with non-allelic homologous recombination mediated by low-copy repeats. "Combined evidence from four human sperm methylome maps, human genome evolution, structural polymorphisms in the human population, and previous genomic and disease studies consistently points to a strong association of germline hypomethylation and genomic instability," the Baylor-led team writes.
PGx Highlights from European Lung Cancer Conference
May 12, 2010
In addition to several PGx studies presented at the conference, the International Association for the Study of Lung Cancer and the European Thoracic Oncology Platform's European EGFR Workshop Group proposed recommendations on EGFR mutation testing in NSCLC when patients are treated with AstraZeneca's Iressa.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.
New to GenomeWeb? Register quickly here.
Related Stories
- Clovis, Avila to Co-develop Targeted NSCLC Drug with Companion Test in Deal Worth up to $209M
May 26, 2010 / Pharmacogenomics Reporter - Biodesix Inks Deal to Test Veristrat in Phase III Clinical Trial for Kadmon Lung Cancer Drug
March 2, 2012 / ProteoMonitor - Yale Researcher Suggests More Focus on EGFR Isoforms Needed in Development of Antibody-Based Drugs
May 20, 2011 / ProteoMonitor - Roche Gets EC Nod for Tarceva as First-Line Therapy in EGFR-mutated NSCLC; Awaits CE Mark for CDx
September 7, 2011 / Pharmacogenomics Reporter - Pfizer Using Qiagen KRAS Test to Study Dacomitinib Head-to-Head Against Tarceva in NSCLC
August 17, 2011 / Pharmacogenomics Reporter